Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ginsenoside Rg3 in Prevention of Postoperative Recurrence of Hepatocellular Carcinoma
NCT01717066Phase 3Completed
- Sponsor
- Shenfeng Biological
- Start
- Nov 2012
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ginsenoside Rg3 in hepatocellular carcinoma (HCC), sponsored by Shenfeng Biological. Started Nov 2012; status: completed.
02
Drugs
ginsenoside Rg3
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT01717066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01717066.